KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Inventory for 16 consecutive years, with $176.5 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 24.4% to $176.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $176.5 million through Dec 2025, up 24.4% year-over-year, with the annual reading at $176.5 million for FY2025, 24.4% up from the prior year.
  • Inventory for Q4 2025 was $176.5 million at Halozyme Therapeutics, down from $185.8 million in the prior quarter.
  • The five-year high for Inventory was $185.8 million in Q3 2025, with the low at $47.8 million in Q1 2022.
  • Average Inventory over 5 years is $119.1 million, with a median of $128.3 million recorded in 2023.
  • The sharpest move saw Inventory dropped 18.14% in 2022, then surged 125.12% in 2023.
  • Over 5 years, Inventory stood at $53.9 million in 2021, then surged by 85.73% to $100.1 million in 2022, then rose by 27.44% to $127.6 million in 2023, then increased by 11.17% to $141.9 million in 2024, then increased by 24.4% to $176.5 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $176.5 million, $185.8 million, and $181.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.